Vigil Neuroscience
Yahoo Finance • last year
Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference
WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today ann... Full story
Yahoo Finance • last year
Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
- Iluzanebart demonstrated favorable safety and tolerability, including no hematologic adverse events - - Clear CNS target engagement and downstream pharmacological activity at 20 mg/kg consistent with Phase 1 data; Directionally supporti... Full story
Yahoo Finance • last year
Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update
– Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in ALSP on track for this quarter – – First participant dosed in Phase 1 study of VG-3927, the first and only small molecule TREM2 agonist in clinical developm... Full story
Yahoo Finance • last year
Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease
WATERTOWN, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today ann... Full story
Yahoo Finance • last year
Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
WATERTOWN, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today ann... Full story
Yahoo Finance • last year
Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP
WATERTOWN, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today an... Full story
Yahoo Finance • last year
Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program
- Announced VG-3927 as lead candidate to enter clinical development for potential treatment of Alzheimer’s Disease - - IND for VG-3927 now open; Phase 1 clinical trial in healthy volunteers allowed to proceed with partial clinical hold re... Full story
Yahoo Finance • last year
Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference
WATERTOWN, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today an... Full story
Yahoo Finance • 2 years ago
Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update
- Partial clinical hold lifted by FDA on VGL101 - - Launched ALSPAware to provide access to no-cost genetic testing and counseling for ALSP - - Appointed distinguished biopharmaceutical industry leader, Samantha Budd Haeberlein, Ph.D., t... Full story
Yahoo Finance • 2 years ago
Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors
WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today anno... Full story
Yahoo Finance • 2 years ago
Vigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101
WATERTOWN, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today an... Full story
Yahoo Finance • 2 years ago
Vigil Neuroscience to Present at Stifel 2023 CNS Days
WATERTOWN, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today an... Full story
Yahoo Finance • 2 years ago
Vigil Neuroscience Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
– Dosed first patient in IGNITE Phase 2 clinical trial to evaluate VGL101 in patients with ALSP – – Presented interim data from natural history study, ILLUMINATE, at Company-hosted ALSP KOL event in December 2022 – – Appointed David Gray... Full story
Yahoo Finance • 2 years ago
Vigil Neuroscience Announces Multiple Presentations on Lead Indication ALSP at the 2023 American Academy of Neurology Annual Meeting
WATERTOWN, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today an... Full story
Yahoo Finance • 2 years ago
Vigil Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today ann... Full story
Yahoo Finance • 2 years ago
Vigil Neuroscience Appoints David Gray, Ph.D., as Chief Scientific Officer and Announces Changes to Executive Team
– Dr. David Gray brings nearly 20 years of preclinical and clinical research and drug development expertise in neurological diseases – – Dr. Spyros Papapetropoulos to depart Vigil to pursue a Chief Executive Officer opportunity – CAMBRID... Full story
Yahoo Finance • 2 years ago
Vigil Neuroscience to Host ALSP KOL Event on December 6, 2022
CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today ann... Full story
Yahoo Finance • 2 years ago
Vigil Neuroscience Reports Third Quarter 2022 Financial Results and Provides Business Update
–Announced interim topline data from Phase 1 trial of VGL101 in healthy volunteers– –On track to initiate Phase 2 proof-of-concept trial in ALSP patients this quarter– –Received Fast Track designation from the FDA for VGL101 in patients... Full story
Yahoo Finance • 2 years ago
Vigil Neuroscience to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today ann... Full story
Yahoo Finance • 2 years ago
Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP
VGL101 demonstrated favorable safety, tolerability and PK profiles in single ascending dose and multiple ascending dose cohorts VGL101 achieved dose dependent, robust and durable decreases in CSF sTREM2 demonstrating proof of target engage... Full story
